Strattera Insurance Denied? How to Appeal Your Atomoxetine ADHD Denial

Strattera (atomoxetine) is the original FDA-approved non-stimulant medication for ADHD, approved for children, adolescents, and adults. Now available generically, it remains an important treatment option — particularly for patients who cannot tolerate or should not use stimulant medications. Yet insurance companies frequently deny Strattera (and generic atomoxetine), particularly when it's prescribed before stimulant medications are tried. If you've received a denial, here's how to appeal.

What Strattera Treats and Why Patients Need It

Strattera (atomoxetine) is a selective norepinephrine reuptake inhibitor (NRI) — the only non-stimulant ADHD medication with FDA approval as a first-line treatment for ADHD across all ages (children 6+, adolescents, and adults).

Unlike stimulants, Strattera:

• Is not a controlled substance (not DEA-scheduled)
• Has no acute misuse potential in the same way stimulants do
• Provides 24-hour coverage including in the morning before medication is taken
• Is appropriate for patients with comorbid anxiety, tic disorders, or substance use concerns
• Does not require specialty pharmacy routing in most states

Strattera is often prescribed when stimulants are contraindicated, have failed, or are not preferred due to patient circumstances. Its steady-state mechanism — gradual improvement over 4–6 weeks rather than immediate effect — also means patients, families, and prescribers may need to advocate more forcefully for the time needed to see results.

Common Denial Reasons for Strattera

Step therapy — stimulants required first: Even though atomoxetine is FDA-approved as a first-line ADHD treatment, many insurance plans classify it as a second-line or non-preferred agent and require a trial of stimulant medication first.

Generic available: Now that atomoxetine is available generically, some plans may deny brand-name Strattera and only cover the generic. If your prescriber wrote for brand Strattera, this may trigger a technical denial.

Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization missing documentation: ADHD diagnosis, age, severity, and functional impairment documentation may be required.

Mental health coverage limitations: Some plans impose stricter prior authorization for psychiatric medications than for comparable medical conditions — a potential parity violation.

Step-by-Step: How to Appeal a Strattera Denial

Step 1: Clarify whether the denial is for brand Strattera or generic atomoxetine. If generic is available and covered, switching the prescription to generic atomoxetine may resolve the issue. If the plan denies even the generic, proceed with the appeal.

Step 2: Document why a stimulant is not the appropriate first choice. If the plan requires stimulants first, your appeal must explain why that step is clinically inappropriate for this patient.

Step 3: Have your prescribing physician write a Letter of Medical Necessity documenting the ADHD diagnosis, functional impairment, specific reasons for choosing a non-stimulant approach, and clinical rationale for atomoxetine.

Step 4: Document prior stimulant trials if applicable. If stimulants were already tried and failed or caused adverse effects, this satisfies the step therapy requirement.

Step 5: File the internal appeal with all documentation and request peer-to-peer review if needed.

Step 6: File an external appeal if the internal appeal fails.

What to Include in Your Strattera Appeal Letter

• Policy number, member ID, and claim reference
• Atomoxetine (generic) or Strattera (brand) — specify which was denied
• ADHD diagnosis documentation and age of patient
• Functional impairment: academic, occupational, or social impairment
• Prior stimulant history if applicable, or explanation of why stimulants are not appropriate
• Specific contraindications or risk factors: cardiovascular history, substance use, anxiety, tics
• Letter of Medical Necessity from prescribing physician or psychiatrist
• FDA approval citation for atomoxetine as first-line ADHD treatment
• Clinical guidelines supporting non-stimulant ADHD treatment
• Mental health parity arguments if step therapy criteria appear excessive
• Request for peer-to-peer review

Success Tips for Strattera Appeals

Make the non-stimulant case specifically. Vague claims that "stimulants are not preferred" won't succeed. Document the specific clinical reason: cardiovascular concern, anxiety disorder comorbidity, tic disorder, substance use disorder in the patient or family, prior stimulant failure with specific adverse effects.

Point out the FDA approval for first-line use. Atomoxetine is specifically FDA-approved as a first-line ADHD treatment — not just as an alternative when stimulants fail. Requiring stimulants first before atomoxetine contradicts the FDA's classification of atomoxetine as a primary ADHD therapy.

For children, emphasize school performance and safety. Academic impact, behavioral concerns in school, and safety (particularly for children with impulsivity in traffic or other dangerous environments) are compelling medical necessity arguments for parents appealing a child's ADHD medication denial.

Invoke mental health parity. If the plan's step therapy requirements for ADHD medications are more restrictive than for non-psychiatric conditions, this may violate MHPAEA.

Fight Back With ClaimBack

Strattera (atomoxetine) is a well-established ADHD medication that has been FDA-approved for decades. If your insurance denied it, you have the right to fight back. ClaimBack walks you through every step of the appeal process.

Start your Strattera appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Common Reasons Insurance Claims Are Denied